Website Redevelopment news and information.

The new look TGA website will be ready soon – For more details visit our project page at

TGA Website Redevelopment 2022
Contact TGA: info@tga.gov.au | 1800 020 653 | More contact info
Translate | Subscribe
Home

Therapeutic Goods Administration (TGA)

Australian Government Department of Health

Main menu

  • Home
  • Safety information
    • Report a problem or side effect
      • Reporting adverse events involving medicines, vaccines or medical devices
      • Report an issue with packaging or storage of a medicine
      • AEMS guidance for health professionals
      • AEMS guidance for sponsors
      • Help us promote adverse event reporting: promotional resources kit
    • Alerts
      • Current year alerts
      • All alerts
    • Recalls
      • About Australian recall actions
      • Recall actions database
      • Uniform recall procedure
    • Prescription opioids
    • Medicine shortages
    • Early warning system
      • Monitoring communications
      • About the Early Warning System
      • Early Warning System: consumer questions and answers
      • Early Warning System: health professional questions and answers
    • Black Triangle Scheme
      • Black Triangle Scheme: Information for sponsors
    • Safety information & education
      • Medicines safety
      • Medical devices safety
      • Database of Adverse Event Notifications (DAEN)
    • COVID-19
    • COVID-19 vaccines
      • COVID-19 vaccine approval process
      • COVID-19 vaccines undergoing evaluation
      • Provisional registrations
      • COVID-19 vaccine safety monitoring and reporting
      • COVID-19 vaccine advertising and import compliance
      • Information for consumers and health professionals
      • Information for sponsors (industry)
      • International collaboration
      • International COVID-19 vaccines recognised by Australia
      • TGA statement on UK government emergency use authorisation related to the COVID Covid-19 vaccine BNT162b2 supplied by Pfizer and BionTECh
    • COVID-19 treatments
      • COVID-19 treatments: Provisional determinations
      • COVID-19 treatments: Provisional registrations
      • COVID-19 treatments: Treatments undergoing evaluation
      • COVID-19 treatments: Advertising compliance
      • COVID-19 treatments: Information for consumers and health professionals
      • COVID-19 treatments: Information for sponsors (industry)
    • COVID-19 tests
      • How testing works for COVID-19
      • COVID-19 point-of-care tests
      • COVID-19 rapid antigen self-tests
      • COVID-19 rapid antigen tests - information for manufacturers and sponsors
      • COVID-19 testing in Australia - information for health professionals
      • Advertising COVID-19 rapid antigen point-of-care tests and self-tests (home use tests)
      • Post market review of COVID-19 point-of-care tests
  • Consumers
    • Travelling with medicines and medical devices
      • Leaving Australia
      • Entering Australia
      • Helpful links for travellers
    • Buying medicines and medical devices online
      • Counterfeit medicines and devices
    • Can I import it?
      • Personal importation scheme
      • Medicinal cannabis: importation and the traveller's exemption
    • Medicines
      • How we regulate medicines
      • Prescription medicines
      • Complementary medicines
      • Over-the-counter (OTC) medicines
      • Vaccines
      • What's on my medicine label?
      • Accessing medicines during a medicines shortage
      • What ingredients are in my medicine?
    • Medical devices
      • Medical devices overview
      • Transvaginal (urogynaecological) surgical mesh hub
      • Breast implant hub
      • Cosmetic injections
      • Medical device cyber security
    • Advertising hub
    • Consumer information & education
      • Safety information for consumers
      • Medicines & medical devices
      • Community Q&A
      • MedSearch | Medicine information search app
      • Other web resources for consumers
      • Medicinal cannabis products
  • Health professionals
    • Accessing unapproved products
      • Special access scheme
      • Authorised prescribers
      • Clinical trials
      • Personal importation scheme
      • Medicine shortages: Information for Health Professionals
      • Medicinal cannabis
      • Nicotine vaping products
      • Six monthly report - supply of unapproved therapeutic goods
    • Medicines
      • Labelling changes: information for health professionals
      • Registration of medicines for the medical termination of early pregnancy
      • Product Information
      • Prescribing medicines in pregnancy database
      • Fast track approval pathways for prescription medicines
      • Product Information safety updates - June 2022
    • Medical devices
      • Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL)
      • Changes to labelling and regulation of hard surface disinfectants (commencing 1 April 2019)
      • Information for medical practitioners on pending up-classification of surgical mesh devices
      • Patient information material for implantable medical devices
      • Importing & supplying medical devices
      • Advice about medical devices for health professionals
    • Biologicals
      • Regulation of stem cell treatments: information for practitioners
    • Other resources
    • Health professional information & education
      • Health professional educational materials
    • Medicines Safety Update
      • Administer vinca alkaloids by intravenous infusion only
      • Antidepressant use and youth suicide
      • Clindamycin capsules and injections - acute kidney injury
      • Clonidine - importance of dosing compliance and safe storage
      • Direct acting oral anticoagulants and risk of recurrent thrombotic events
      • Erenumab and hypertension
      • Fluoroquinolone antibiotics and risk of aortic aneurysm/dissection
      • Medicines Safety Update Volume 9 Number 3, August-September 2018
      • Medicines Safety Update, Volume 9, Number 2, June 2018
      • Medicines Safety Update, Volume 9, Number 4, December 2018
      • Minocycline and agranulocytosis
      • Propylthiouracil and carbimazole – use in pregnancy
      • SGLT2 inhibitors approved for T2DM only
      • Tenofovir alafenamide and renal adverse effects
      • Update - fluoroquinolone antibiotics and adverse events
  • Industry
    • SME Assist
      • Regulation essentials
      • Workshops and events
      • Podcasts
      • SME guidance material
      • Educational videos
      • Interactive decision tools
      • Case studies
      • Useful resources for business
      • Understanding ingredient requirements
    • Regulation basics
      • How therapeutic goods are regulated in Australia
      • Australian Register of Therapeutic Goods
      • Industry educational materials
      • Legislation & legislative instruments
      • Advertising hub
      • Labelling & packaging
      • Ingredients in therapeutic goods
      • Exporting therapeutic goods
      • Importing therapeutic goods
      • Clinical trials
      • Cosmetics
      • International scientific guidelines
      • Safety information for industry
      • Medicine shortages
      • Review of real world evidence and patient reported outcomes
    • Advertising therapeutic goods
      • Getting started
      • Complying with advertising requirements
      • Learning resources
      • Enforcement and outcomes
      • News and reports
      • Consultation and independent reviews
      • Advertising Code FAQs
      • Guidance on applying the Advertising Code rules
      • Obtaining approved COVID-19 rapid antigen tests
      • Testimonials and endorsements in advertising
      • The Therapeutic Goods Advertising Code
    • Prescription medicines
      • Australian Regulatory Guidelines for Prescription Medicines
      • Prescription medicines regulation basics
      • Standards and guidelines
      • Forms for prescription medicine sponsors
      • Regulatory decisions and notices
    • Over-the-counter medicines
      • OTC medicines regulation basics
      • Standards, guidelines and publications
      • Forms for OTC medicine sponsors
      • Regulatory decisions and notices
    • Complementary medicines
      • Complementary medicine regulation basics
      • Standards, guidelines and publications
      • Forms for complementary medicine sponsors
      • Complementary medicines reforms
      • Regulatory decisions and notices
    • Sunscreens
      • Sunscreens regulation basics
      • Standards, guidelines and publications
      • Sunscreen reforms
    • Medical devices & IVDs
      • Face masks and COVID-19
      • Medical devices regulation basics
      • Overview of medical devices and IVD regulation
      • Unique Device Identification system
      • IVD medical devices regulation basics
      • Standards, guidelines and publications
      • Forms for medical device & IVD sponsors
      • Medical devices reforms
      • Regulatory decisions and notices
    • Biologicals
      • Australian Regulatory Guidelines for Biologicals
      • Regulatory framework for biologicals
      • Biological standards
      • Forms for the biologicals industry
      • Regulatory decisions and notices
    • Blood and blood components
      • Regulation of blood
      • Regulation of platelet-rich plasma (PRP), platelet-rich fibrin (PRF) and conditioned serum
      • Forms for the blood and blood components industry
    • Advanced therapies
    • Other therapeutic goods
      • Disinfectants, sterilants and sanitary products
      • Tampons & menstrual cups
    • Manufacturing therapeutic goods
      • Manufacturing basics
      • Manufacturing medicines
      • Manufacturing medical devices & IVDs
      • Manufacturing biologicals
      • Manufacturing blood and blood components
      • Manufacturing inspections
      • Forms for manufacturers
      • Notices for manufacturers
      • Notices about GMP clearance
      • Guidance on the management of GMP compliance signals
    • Scheduling of medicines & poisons
      • Scheduling basics
      • Scheduling committees meeting dates and decisions timeframes
      • The Poisons Standard (the SUSMP)
      • Public notices about scheduling
      • State/Territory scheduling information
  • About the TGA
    • TGA basics
      • Who we are & what we do
      • What the TGA doesn't do
      • Structure
      • TGA plans & reports
      • TGA reforms
      • Publications
      • Forms
      • Freedom of information
      • Acronyms & glossary
      • TGA Internet site
      • Social media
    • Contact the TGA
      • How can we help?
      • TGA customer service standards
      • Report a perceived breach or questionable practices
      • Website feedback or error reporting
      • Translate this website
    • Educational materials
      • For university students
      • Education priorities 2018-19
    • Compliance and enforcement hub
      • Compliance management
      • Compliance actions and outcomes
      • News and information
      • Report a breach
    • Regulatory decisions & notices
      • Consent to import, supply or export goods that do not comply with standards
      • Cancellation requested by the sponsor - regulatory actions
      • Failure to pay annual charges - regulatory actions
      • TGA laboratory testing results
      • AUST numbers on medicine labels
      • S19A approval notices
    • Committees
      • TGA statutory advisory committees
      • Other committees
    • Employment & job vacancies
      • Working for the TGA
      • Recruitment information
    • Fees and payments
      • Schedule of fees and charges
      • Payment options
      • Information & notices about TGA fees & payments
      • Cost recovery implementation statements
      • Forms (fees and payments)
      • Annual Charge Exemption (ACE) scheme
    • TGA Business Services
      • TGA Business services: getting started with the TGA
      • TGA Business services - how to use the site
      • TGA Business Services forms
    • International
      • International activities
      • International cooperation
      • Use of international assessments
      • TGA international engagement strategy
      • Links to international agencies & organisations
    • TGA Internet site archive
      • Archived behind the news articles
      • Archived consultations & reviews
      • Archived newsletters and articles
      • Archived presentations
      • Archived regulatory decisions & notices
      • Archived TGA publications
  • News room
    • News & public notices
      • Latest news & updates
      • Media releases & statements
      • Behind the news
      • Newsletters & articles
      • Subscribe to updates
      • TGA tenders
      • TGA laboratory testing reports
    • Consultations & reviews
      • Open consultations & reviews
      • Closed consultations & reviews
      • About consultations
      • Medicines and Medical Devices Regulation Review
    • Events, training & presentations
      • Events & training
      • Presentations
    • Blog
    • Website redevelopment project (WRP)

For information on accessing rapid antigen tests and what to do if you test positive, go to COVID-19 testing on the Department of Health website.

About the TGA

  • TGA basics
  • Contact the TGA
  • Educational materials
  • Compliance and enforcement hub
  • Regulatory decisions & notices
  • Committees
  • Employment & job vacancies
  • Fees and payments
  • TGA Business Services
    • TGA Business services: getting started with the TGA
    • TGA Business services - how to use the site
    • TGA Business Services forms
  • International
  • TGA Internet site archive
Therapeutic Goods Administration (TGA)
Decrease the text size Increase the text size Print this page Share

You are here

Home » About the TGA » TGA Business Services

TGA Business Services forms

These forms are used by sponsors, agents and manufacturers to apply for access to TGA Business Services.

  • Organisation details form
  • Add or remove an Agent from your organisation form
  • Add or remove a connection to your manufacturing organisation
  • Updating organisation administrator
  • URL:https://www.tga.gov.au/node/3241
  • Copyright
  • Privacy
  • Disclaimer
  • Security
  • Acronyms & glossary
  • Sitemap
  • A-Z guide
  • Contact the TGA
  • Freedom of Information

Sitemap Navigation

  • Home
  • Safety information
    • Report a problem or side effect
    • Alerts
    • Recalls
    • Prescription opioids
    • Medicine shortages
    • Early warning system
    • Black Triangle Scheme
    • Safety information & education
    • COVID-19
    • COVID-19 vaccines
    • COVID-19 treatments
    • COVID-19 tests
  • Consumers
    • Travelling with medicines and medical devices
    • Buying medicines and medical devices online
    • Can I import it?
    • Medicines
    • Medical devices
    • Advertising hub
    • Consumer information & education
  • Health professionals
    • Accessing unapproved products
    • Medicines
    • Medical devices
    • Biologicals
    • Other resources
    • Health professional information & education
    • Medicines Safety Update
  • Industry
    • SME Assist
    • Regulation basics
    • Advertising therapeutic goods
    • Prescription medicines
    • Over-the-counter medicines
    • Complementary medicines
    • Sunscreens
    • Medical devices & IVDs
    • Biologicals
    • Blood and blood components
    • Advanced therapies
    • Other therapeutic goods
    • Manufacturing therapeutic goods
    • Scheduling of medicines & poisons
  • About the TGA
    • TGA basics
    • Contact the TGA
    • Educational materials
    • Compliance and enforcement hub
    • Regulatory decisions & notices
    • Committees
    • Employment & job vacancies
    • Fees and payments
    • TGA Business Services
    • International
    • TGA Internet site archive
  • News room
    • News & public notices
    • Consultations & reviews
    • Events, training & presentations
    • Blog
    • Website redevelopment project (WRP)
  • www.australia.gov.au
  • www.health.gov.au
  • www.odc.gov.au

The Therapeutic Goods Administration is part of the Health Products Regulation Group